Scarica l'app Stockscreener
779.36
1.48%
11.40
Dopo l'orario di chiusura:
778.00
-1.36
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$767.96
Aprire:
$765.84
Volume 24 ore:
812.52K
Relative Volume:
0.74
Capitalizzazione di mercato:
$81.91B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.66
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+3.55%
1M Prestazione:
+3.10%
6M Prestazione:
+52.90%
1 anno Prestazione:
+11.04%
Intervallo 1D:
$765.09
$783.60
Intervallo di 1 settimana:
$734.72
$783.60
Portata 52W:
$476.49
$790.98
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
779.36 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.73 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
852.04 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.76 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Diabetic Retinopathy Market to See Booming Growth 2025-2032 | - openPR.com
Wedge Capital Management L L P NC Buys New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc. - MarketBeat
Regeneron: The Turnaround Is Gaining Steam - Seeking Alpha
Voya Investment Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Corient Private Wealth LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Should Regeneron’s Clarified Eylea Biosimilar Timeline Reshape How REGN Investors View Its Core Franchise? - simplywall.st
Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06 - TipRanks
Published on: 2025-12-19 17:35:07 - Улправда
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stockSwing Trade & Daily Technical Forecast Reports - DonanımHaber
Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating - marketscreener.com
Texas Permanent School Fund Corp Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. (TEVA:NYSE) - Seeking Alpha
Alvotech and Teva Pharmaceuticals Announce Settlement Agreement with Regeneron for AVT06 Biosimilar Launch in the U.S. - Quiver Quantitative
Eye disease patients may see new Eylea alternative in US from late 2026 - Stock Titan
Regeneron Pharmaceuticals (REGN) Stock Price, Quote, News & History - Benzinga
Will Regeneron Pharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Weekly Top Performers Watchlists - Улправда
Clinical momentum lifts biopharma stocks into year-end - BioWorld MedTech
Why (REGN) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration - simplywall.st
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yieldQuarterly Performance Summary & Technical Confirmation Trade Alerts - Улправда
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sicart Associates LLC Makes New $3.93 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leerink Partners raises Regeneron stock price target to $873 on growth outlook - Investing.com UK
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Is Regeneron Still Attractively Priced After Its Recent Share Price Surge? - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple MyelomaSlideshow (NASDAQ:REGN) 2025-12-16 - Seeking Alpha
Westwood Holdings Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Insight Wealth Strategies LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stock Watch: Regeneron Caught Between Success And Expiry - Citeline News & Insights
Praxis Investment Management Inc. Has $762,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financia - GuruFocus
Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera - Yahoo Finance
MASTERINVEST Kapitalanlage GmbH Makes New $1.14 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Headlands Technologies LLC - MarketBeat
Bayer-Regeneron Aflibercept 8 mg recommended for EU approval for third retinal indication - Medical Dialogues
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow - sharewise.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $768.00 Price Target at Morgan Stanley - MarketBeat
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow - The Motley Fool
The Manufacturers Life Insurance Company Has $199.26 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Game Creek Capital LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellevue Group AG Sells 1,779 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Regeneron Pharmaceuticals (REGN) Receives Updated Analyst Ratings from Morgan Stanley | REGN Stock News - GuruFocus
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Paroxysmal Nocturnal Hemoglobinuria Market to Experience - openPR.com
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.87%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):